Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7758273 | 0.90 | HDAC1 (0.63) | FFAR1CYP1A2TAAR1HDAC1HDAC6 | |
| SCHEMBL29669893 | 0.90 | HDAC1 (0.63) | FFAR1CYP1A2TAAR1HDAC1HDAC6 | |
| Phenyl Propionic Acid SCHEMBL28549079 | 0.90 | RAB9A (0.60) | FFAR1CYP1A2PLA2G4AHDAC1HDAC6 | |
| SCHEMBL28188589 | 0.89 | HDAC1 (0.70) | CYP1A2TAAR1HDAC1HDAC6MTNR1A | |
| SCHEMBL1206248 | 0.89 | HDAC1 (0.70) | CYP1A2TAAR1HDAC1HDAC6MTNR1A | |
| Phenyl Propionic Acid SCHEMBL28910944 | 0.89 | RAB9A (0.59) | FFAR1CYP1A2PLA2G4AHDAC1HDAC6 | |
| SCHEMBL3463706 | 0.88 | CYP1A2 (0.56) | FFAR1CYP1A2PLA2G4ATAAR1HDAC1 | |
| SCHEMBL7332474 | 0.88 | TAAR1 (0.61) | TAAR1HDAC1HDAC6RAB9AMTNR1A | |
| SCHEMBL25035334 | 0.87 | HDAC1 (0.72) | CYP1A2HDAC1HDAC6MTNR1AMTNR1B | |
| SCHEMBL17274767 | 0.87 | HDAC1 (0.72) | CYP1A2HDAC1HDAC6MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 476 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| US-12497636-B2 | Recombinant Saccharomyces cerevisiae cells for cannabinoid production | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-12-16 | — | — | US | claimed |
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2025-05-20 | — | — | US | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-118130691-A | Method for detecting characteristic components of typical aroma in main stream smoke of cigarettes | 上海烟草集团有限责任公司 | 2024-06-04 | — | — | CN | claimed |
| CN-117310059-B | Plasma metabolism marker combination for early diagnosis or monitoring of Crohn disease and application thereof | 中国人民解放军总医院 | 2024-02-02 | — | — | CN | claimed |
| CN-117310059-A | Plasma metabolism marker combination for early diagnosis or monitoring of Crohn disease and application thereof | 中国人民解放军总医院 | 2023-12-29 | — | — | CN | claimed |
| US-20220194909-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2022-06-23 | — | — | US | claimed |
| WO-2020210922-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11Β-HSD1) | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2020-10-22 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| CN-102797043-B | Medicinal molecular fragment library and construction process thereof | Tianli (Tianjin) Technology Co., Ltd. (CN) | 2015-11-25 | — | — | CN | claimed |
| CN-102797043-A | Medicinal molecular fragment library and construction method thereof | CBB NETWORK CO LTD | 2012-11-28 | — | — | CN | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| CN-100497286-C | Preparation method of 2,3-bihydrogen-1-indenone and its derivative | WUHAN ZHONGXIN CHEMICAL CO LTD (CN) | 2009-06-10 | — | — | CN | claimed |
| CN-1903818-A | Preparation method of 2,3-bihydrogen-1-indenone and its derivative | WUHAN ZHONGXIN CHEMICAL CO LTD (CN) | 2007-01-31 | — | — | CN | claimed |
| CN-1029932-C | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers | BIORESEARCH INC (US) | 1995-10-11 | — | — | CN | claimed |
| CN-1060770-A | The sweetness inhibitor that contains substantially tasteless is as bitter inhibitor or contain the absorbed thing of the bitter inhibitor of substantially tasteless as sweetness inhibitor | BIORESEARCH INC (US) | 1992-05-06 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | FFAR1 4669/4885CYP1A2 4223/4885PLA2G4A 1572/4885 |
| US-20220194909-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) | HSD11B1, HSD11B2, CYP11B1 | FFAR1 695/4885CYP1A2 84/4885PLA2G4A 4335/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | FFAR1 4669/4885CYP1A2 4223/4885PLA2G4A 1572/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | FFAR1 4669/4885CYP1A2 4223/4885PLA2G4A 1572/4885 |
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | HSD11B1, HSD11B2, HSD17B1 | FFAR1 623/4885CYP1A2 91/4885PLA2G4A 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.